In yesterday’s Wall Street session, Taysha Gene Therapies Inc (NASDAQ:TSHA) shares traded at $3.10, up 4.73% from the previous session.
TSHA stock price is now 55.27% away from the 50-day moving average and 69.45% away from the 200-day moving average. The market capitalization of the company currently stands at $579.76M.
With the price target reduced from $14 to $1.50, Jefferies Downgraded its rating from Buy to Hold for Taysha Gene Therapies Inc (NASDAQ: TSHA). On January 27, 2023, Morgan Stanley Downgraded its previous ‘Overweight’ rating to ‘Equal-Weight’ on the stock reducing its target price from $23 to quote $3, while ‘Goldman’ rates the stock as ‘Neutral’
In other news, Manning Paul B, 10% Owner bought 100,000 shares of the company’s stock on Nov 17 ’23. The stock was bought for $163,000 at an average price of $1.63. Upon completion of the transaction, the 10% Owner now directly owns 16,566,667 shares in the company, valued at $51.36 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 24 ’23, Chief Financial Officer Alam Kamran sold 33,000 shares of the business’s stock. A total of $76,890 was realized by selling the stock at an average price of $2.33. This leaves the insider owning 258,042 shares of the company worth $0.8 million. A total of 31.24% of the company’s stock is owned by insiders.
During the past 12 months, Taysha Gene Therapies Inc has had a low of $0.50 and a high of $3.89. As of last week, the company has a debt-to-equity ratio of 0.82, a current ratio of 4.06, and a quick ratio of 4.06. The fifty day moving average price for TSHA is $2.0201 and a two-hundred day moving average price translates $1.8408 for the stock.
The latest earnings results from Taysha Gene Therapies Inc (NASDAQ: TSHA) was released for Dec, 2023. According to the Biotechnology Company, earnings per share came in at $0.92, beating analysts’ expectations of -$0.11 by 1.03. This compares to -$0.96 EPS in the same period last year. The net profit margin was -722.06% and return on equity was -294.04% for TSHA. For the current quarter, analysts expect TSHA to generate $1.49M in revenue.
